{"References": [{"title": "Combining immune checkpoint inhibitors: established and emerging targets and strategies", "authors": "Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.", "journal": "Nature Reviews Cancer", "year": "2018", "volumes": "18", "first page": "25", "last page": "37", "DOI": "10.1038/nrc.2017.108"}, {"title": "Collateral sensitivity to combined therapies: new insights into cancer treatment", "authors": "Zhao, Bin, Hemann, Michael T.", "journal": "Trends in Cancer", "year": "2020", "volumes": "6", "first page": "508", "last page": "517", "DOI": "10.1016/j.trecan.2020.03.007"}, {"title": "Synergy between immune checkpoint blockade and targeted therapies in cancer treatment", "authors": "Sharma, Padmanee, Hu-Lieskovan, Siwen, Wargo, Jennifer A., Ribas, Antoni", "journal": "Nature Reviews Immunology", "year": "2017", "volumes": "17", "first page": "267", "last page": "284", "DOI": "10.1038/nri.2017.29"}, {"title": "Independent action and synergy in combination therapy: a model-based approach", "authors": "Fitzgerald, John B., Schoeberl, Birgit, Nielsen, Ulrik B., Sorger, Peter K.", "journal": "Nature Chemical Biology", "year": "2006", "volumes": "2", "first page": "458", "last page": "466", "DOI": "10.1038/nchembio817"}, {"title": "Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?", "authors": "Pardoll, Drew M.", "journal": "Science", "year": "2012", "volumes": "338", "first page": "61", "last page": "68", "DOI": "10.1126/science.1220939"}, {"title": "The evolving landscape of immune checkpoint inhibitor combination therapy", "authors": "Hodi, F. Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Cowey, C. Lance, Lao, Christopher D., Wagstaff, John, Dummer, Reinhard, Schadendorf, Dirk", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36", "first page": "2983", "last page": "2983", "DOI": "10.1200/JCO.2018.36.15_suppl.2983"}, {"title": "Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer", "authors": "Zhao, Bin, Hemann, Michael T.", "journal": "Nature Communications", "year": "2016", "volumes": "7", "first page": "12351", "last page": "12351", "DOI": "10.1038/ncomms12351"}, {"title": "Rational combinations of immunotherapeutics that target discrete pathways", "authors": "Melero, Ignacio, Berman, David M., Aznar, Miguel A., Korman, Alan J., Gracia, Jose L., Haanen, John", "journal": "Journal for ImmunoTherapy of Cancer", "year": "2015", "volumes": "3", "first page": "28", "last page": "28", "DOI": "10.1186/s40425-015-0078-0"}, {"title": "The synergy of targeted therapy and immunotherapy in cancer treatment", "authors": "Ribas, Antoni, Wolchok, Jedd D.", "journal": "Nature Reviews Clinical Oncology", "year": "2018", "volumes": "15", "first page": "375", "last page": "386", "DOI": "10.1038/s41571-018-0007-1"}, {"title": "Combining targeted therapy and immune checkpoint inhibitors in cancer treatment: Mechanisms and clinical applications", "authors": "Zhang, Yifan, Zhang, Zhen", "journal": "Frontiers in Immunology", "year": "2019", "volumes": "10", "first page": "683", "last page": "683", "DOI": "10.3389/fimmu.2019.00683"}]}